Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

NCT07667335 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Bladder Giant Cell Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Stage IIIB Bladder Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8
Stage IV Renal Pelvis Cancer AJCC v8
Stage IV Ureter Cancer AJCC v8
Unresectable Bladder Urothelial Carcinoma
Unresectable Renal Pelvis Urothelial Carcinoma
Unresectable Ureter Urothelial Carcinoma

Interventions

DRUG: Quemliclustat
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Enfortumab Vedotin
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
PROCEDURE: Biopsy Procedure

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]